The Amgen earnings transcript indicates a strong start to 2016, with growth in revenue and earnings, driven by product sales and supported by robust launches of new products like REPATHA and Kyprolis. The company has increased its guidance for 2016, signaling confidence in continued performance. Additionally, Amgen's active pipeline and strategic international expansion efforts reinforce a positive outlook. However, challenges like high prescription rejection rates for REPATHA due to insurance hurdles could dampen enthusiasm. Overall, the positive financial results and raised guidance suggest a likely positive short-term impact on the stock.

[1]